A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Did Not Respond to Therapy

PHASE2CompletedINTERVENTIONAL
Enrollment

117

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

February 28, 2010

Study Completion Date

February 28, 2010

Conditions
Hepatitis C
Interventions
DRUG

Telaprevir

Tablet

DRUG

Ribavirin

Tablet

DRUG

Pegylated interferon alfa 2a

Solution for Injection

Trial Locations (62)

40225

Uniklinik Duesseldorf, Düsseldorf

Unknown

Birmingham

Los Angeles

Kaiser Permanente Internal Medicine, San Diego

San Francisco

University of Colorado Health Sciences Center, Denver

South Denver Gastroenterology, Englewood

University of Florida, Gainesville

Borland-Groover Clinic, Jacksonville

Mayo Clinic Jacksonville, Jacksonville

University of Miami Center for Liver Diseases, Miami

Sarasota

Atlanta Gastroenterology Associates, Atlanta

University of Chicago, Chicago

Indianapolis

Digestive and Liver Disease Clinic, Baton Rouge

Virology Treatment Center, Maine Medical Center, Portland

Johns Hopkins University, Baltimore

Beth Israel Deaconess Medical Center, Boston

University of Massachusetts Memorial Medical Center, Worcester

Henry Ford Hospital, Detroit

St Louis University, St Louis

The Nebraska Medical Center, Omaha

University of New Mexico, Albuquerque

North Shore University Hospital, Manhasset

New York

Duke University Medical Center, Durham

University of Cincinnati, Cincinnati

Cleveland

Penn State Hershey Medical Center, Hershey

University of Pittsburgh Medical Center, Pittsburgh

Columbia Gastroenterology Associates, PA, Columbia

Memphis Gastroenterology Group, Germantown

Liver Institute at Methodist Dallas, Dallas

Houston

Alamo Medical Research, San Antonio

Annandale

University of Virginia Health Systems, Charlottesville

Metropolitan Research, Fairfax

McGuire DVAMC, Richmond

Vienna

University of Calgary Medical Clinic, Calgary

University of Alberta, Edmonton

University of British Columbia Vancouver General Hospital, Vancouver

Winnipeg

Toronto

Hospital Henri Mondor, Créteil

Lyon

Nice

Paris

Pessac

Vandœuvre-lès-Nancy

Berlin

Universitatsklinikum Bonn, Bonn

University of Cologne, Cologne

Frankfurt

Hanover

Academic Medical Center, Amsterdam

Leiden University Medical Center, Leiden

Erasmus MC Medical Center, Rotterdam

Fundacion de Investigation de Diego, Santurce

London

All Listed Sponsors
collaborator

Tibotec, Inc

INDUSTRY

lead

Vertex Pharmaceuticals Incorporated

INDUSTRY

NCT00535847 - A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Did Not Respond to Therapy | Biotech Hunter | Biotech Hunter